2-(Methylamino)-1-methylsulfanylpentan-3-one

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-(Methylamino)-1-methylsulfanylpentan-3-one
• 英文别名: 2-(methylamino)-1-methylsulfanylpentan-3-one
• 化学式: C₇H₁₅NOS
• 分子量: 161.27
• InChiKey: IEWLYKLNPNNOHP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  10
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  54.4
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• WT1 ANTIGEN PEPTIDE CONJUGATE VACCINE
  申请人：Sumitomo Dainippon Pharma Co., Ltd.

  公开号：US20150238587A1

  公开（公告）日：2015-08-27

  A compound represented by the formula (1): wherein X a and Y a are each a single bond and the like, cancer antigen peptide A is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, R 1 is a hydrogen atom, a group represented by the formula (2): wherein X b and Y b are each a single bond and the like, cancer antigen peptide B has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide consisting of 7-30 amino acid residues, or cancer antigen peptide C, and cancer antigen peptide C has a sequence different from that of the cancer antigen peptide A, and is an MHC class I-restricted WT1 peptide or an MHC class II-restricted WT1 peptide, consisting of 7-30 amino acid residues containing one cysteine residue, or a salt thereof, and the like.

  由公式（1）表示的化合物： 其中Xa和Ya都是单一键等，癌抗原肽A是一种由7-30个氨基酸残基组成的MHC I类限制性WT1肽，R1是一个氢原子，由公式（2）表示的基团： 其中Xb和Yb都是单一键等，癌抗原肽B具有与癌抗原肽A不同的序列，并且是一种由7-30个氨基酸残基组成的MHC I类限制性WT1肽，或者癌抗原肽C，癌抗原肽C具有与癌抗原肽A不同的序列，是一种由7-30个氨基酸残基组成的MHC I类限制性WT1肽或MHC II类限制性WT1肽，含有一个半胱氨酸残基，或其盐类等。
• CONJUGATE VACCINE USING TRIMMING FUNCTION OF ERAP1
  申请人：SUMITOMO DAINIPPON PHARMA CO., LTD.

  公开号：US20160045582A1

  公开（公告）日：2016-02-18

  The present invention provides a compound represented by the formula (1): wherein X a and Y a are each a single bond or the like, cancer antigen peptide A is an MHC class I-restricted cancer antigen peptide, and R 1 is a hydrogen atom; a group represented by the formula ( 2 ): wherein X b and Y b are each a single bond or the like, and cancer antigen peptide B is different from the cancer antigen peptide A and is an MHC class I or II-restricted cancer antigen peptide; a group represented by the formula (3): wherein X c and Y c are each a single bond or the like, and cancer antigen peptide C is an MHC class II-restricted cancer antigen peptide; or cancer antigen peptide D, wherein the cancer antigen peptide D is an MHC class I or II-restricted cancer antigen peptide containing one cysteine residue, or a salt thereof, for example.

  该发明提供了一种化合物，其表示为公式（1）：其中Xa和Ya分别是单键或类似物，癌抗原肽A是一种MHC I类限制性癌抗原肽，R1是氢原子；一种表示为公式（2）的基团：其中Xb和Yb分别是单键或类似物，癌抗原肽B与癌抗原肽A不同，并且是一种MHC I或II类限制性癌抗原肽；一种表示为公式（3）的基团：其中Xc和Yc分别是单键或类似物，癌抗原肽C是一种MHC II类限制性癌抗原肽；或者癌抗原肽D，其中癌抗原肽D是一种含有一个半胱氨酸残基的MHC I或II类限制性癌抗原肽，或其盐。
• MODIFIED FC PROTEINS COMPRISING SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES OF THE SAME, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE
  申请人：Sutro Biopharma, Inc.

  公开号：US20200283543A1

  公开（公告）日：2020-09-10

  Provided herein are modified Fc proteins comprising non-natural amino acid residues at site-specific positions, conjugates of the modified Fc proteins for therapy or diagnosis, compositions comprising the modified Fc proteins and conjugates thereof, methods of their production and methods of their use. The modified Fc proteins and conjugates are useful for methods of treatment and prevention, methods of detection and methods of diagnosis.
• HUMAN INTERLEUKIN-2 CONJUGATES BIASED FOR THE INTERLEUKIN-2 RECEPTOR BETA GAMMAc DIMER AND CONJUGATED TO A NONPEPTIDIC, WATER-SOLUBLE POLYMER
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20210340207A1

  公开（公告）日：2021-11-04

  Interleukin-2 (IL-2) conjugates comprising at least one or more amino acid substitutions that bias binding to the IL-2 receptor βγ c dimer over binding the IL-2 receptor αβγ c trimer and a non-natural amino acid at or near the N-terminus conjugated to a water-soluble polymer are described. The IL-2 conjugates are useful for treatment and prevention of cell proliferation and cancer in a patient.
• US9181302B2
  申请人：——

  公开号：US9181302B2

  公开（公告）日：2015-11-10